- Home
- TSHA vs AUPH Comparison
TSHA vs AUPH Comparison
Compare TSHA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- AUPH
- Stock Information
- Founded
- TSHA 2019
- AUPH 1993
- Country
- TSHA United States
- AUPH Canada
- Employees
- TSHA N/A
- AUPH N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- AUPH Health Care
- Exchange
- TSHA Nasdaq
- AUPH Nasdaq
- Market Cap
- TSHA 1.4B
- AUPH 1.6B
- IPO Year
- TSHA 2020
- AUPH 1999
- Fundamental
- Price
- TSHA $3.84
- AUPH $14.57
- Analyst Decision
- TSHA Strong Buy
- AUPH Strong Buy
- Analyst Count
- TSHA 9
- AUPH 3
- Target Price
- TSHA $10.22
- AUPH $17.67
- AVG Volume (30 Days)
- TSHA 4.1M
- AUPH 1.7M
- Earning Date
- TSHA 11-04-2025
- AUPH 11-04-2025
- Dividend Yield
- TSHA N/A
- AUPH N/A
- EPS Growth
- TSHA N/A
- AUPH N/A
- EPS
- TSHA N/A
- AUPH 0.55
- Revenue
- TSHA $6,310,000.00
- AUPH $265,808,000.00
- Revenue This Year
- TSHA N/A
- AUPH $17.33
- Revenue Next Year
- TSHA N/A
- AUPH $14.31
- P/E Ratio
- TSHA N/A
- AUPH $26.58
- Revenue Growth
- TSHA N/A
- AUPH 20.62
- 52 Week Low
- TSHA $1.05
- AUPH $6.55
- 52 Week High
- TSHA $5.51
- AUPH $16.20
- Technical
- Relative Strength Index (RSI)
- TSHA 37.78
- AUPH 72.40
- Support Level
- TSHA $3.89
- AUPH $13.34
- Resistance Level
- TSHA $4.55
- AUPH $16.20
- Average True Range (ATR)
- TSHA 0.39
- AUPH 0.72
- MACD
- TSHA -0.19
- AUPH 0.29
- Stochastic Oscillator
- TSHA 8.99
- AUPH 65.68
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.